Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer

Inclusion Criteria: Previously untreated patients with unresectable or metastatic adenocarcinoma of the pancreas ECOG Performance Status 0-2 18 years of age or older Radiographically measurable disease Expected survival of at least 4 months Creatinine of </= 2.0 Adequate hepatic function Adequate hematopoietic function Use of effective means of contraception in subjects of child-bearing potential Exclusion Criteria: Warfarin anticoagulation Prior treatment with a tyrosine kinase inhibitor, EGFR inhibitor, or VEGF inhibitor Coexistent malignant disease Current or recent (within 4 weeks) participation in a clinical trial Pregnancy Documented invasion of adjacent organs or major blood vessels Blood pressure of > 150/100mmHg Unstable angina NYHA Grade II or greater congestive heart failure History of myocardial infarction or stroke within 6 months Clinically significant peripheral vascular disease Evidence of bleeding diathesis of coagulopathy Presence of CNS or brain metastases Major surgical procedure, open biopsy, or significant traumatic event within 28 days Minor surgical procedures, fine needle aspirations or core biopsies within 7 days History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months Serious non-healing wound, ulcer or bone fracture